7T metabolic MRI in glioma & epilepsy

7T metabolic MRI in glioma & epilepsy - GliMEpi

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55209

Enrollment

Registered

2020-12-08

Start date

2021-06-14

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Aged 16 years or over and able to exercise their free will (capacitated); • Diagnosed with glioma-associated epilepsy or focal epilepsy with a relevant lesion on conventional MRI or PET; • Scheduled for surgical treatment; • Informed and having given informed consent

Exclusion criteria

Exclusion criteria: • The presence of claustrophobia; • MRI-specific exclusion criteria, such as metallic implants and pregnancy; • Refusal or inability to provide informed consent.

Design outcomes

Primary

Measure	Time frame
Metabolic imaging measures of different molecules of interest in glioma tissue (including but not limited to: N-acetylaspartate (NAA), choline, creatine, 2HG and cystathionine) and epileptogenic tissue (including but not limited to glutamate, gamma-aminobutyric acid (GABA) and iron) as acquired with 7T metabolic MRI.	—

Secondary

Measure	Time frame
Comparison of the metabolic imaging measures of different molecules of interest with histopathological measures.	—

Countries

Netherlands

Outcome results